GoPlus launches AgentGuard to build an execution-level security boundary for OpenClaw
Foresight News reported that GoPlus Security has launched a security Skill called "AgentGuard," specifically designed for AI Agents with real-world execution capabilities, aiming to provide execution-level security protection for OpenClaw.
As AI Agents begin to possess real execution abilities (such as command execution, file reading and writing, service invocation, and on-chain transactions and signatures), the risks have escalated from "incorrect answers" to execution risks that could directly cause system damage, data leakage, or financial loss. Leveraging its long-term technical expertise in Web3 on-chain security and transaction risk control, GoPlus has shifted security capabilities to precede AI execution.
GoPlus AgentGuard uses a "runtime interception + on-demand deep scanning" mechanism to intercept, confirm, or allow high-risk behaviors, assessing action risks before AI Agents execute them. This is a dedicated execution-level security mechanism to prevent AI Agents from "arbitrary execution, unauthorized execution, or dangerous execution," enabling users to use OpenClaw more safely. AgentGuard is now open source and available for AI Builders and developers.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y
As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
Crypto prices
More
